Author
Listed:
- Dominique Claude Mossebo
(University of Yaoundé 1, Cameroon)
- Blondo-Pascal Metsebing
(University of Yaoundé 1, Cameroon)
- Romuald Oba
(University of Yaoundé 1, Cameroon)
- Fabrice Tsigaing Tsigaing
(University of Yaoundé 1, Cameroon)
- Leif Ryvarden
(University of Oslo, Norway)
- Thierry Youmbi Fonkui
(University of Johannesburg, South Africa)
- Charlotte Mungoh Tata
(University of Johannesburg, South Africa)
- Derek Tantoh Ndinteh
(University of Johannesburg, South Africa)
Abstract
Antifungal and antibacterial activities of crude extracts of 3 tropical mushrooms including Pleurotus sajor-caju, Pleurotus tuber-regium and Lentinus squarrosulus were investigated on eleven species of bacterial and three of fungal human pathogens. For the pathogenic fungi, the Minimal Inhibitory Concentration (MIC) of carpophore extracts ranged from 0.39 mg/mL to 6.25 mg/mL for Candida albicans, 0.78 mg/mL to 6.25 mg/mL for Aspergillus fumigetus, and 1.56 mg/mL to 6.25 mg/mL for Aspergillus ochraceus. For bacteria, the MIC values ranged from 6.25 mg/mL to 12.5 mg/mL on most Gram positive strains including Bacillus subtilis, Enterococcus faecalis, Staphylococcus aureus and Mycobacterium smegmatis. This MIC value was the same (12.5 mg/mL) for the 3 crude extracts tested on Staphylococcus epidermidis for the Gram positive strains. Gram negative bacteria were generally less sensitive to crude extracts with higher MIC values ranging from 6.25 mg/mL to 12.5 mg/mL for Escherichia coli and Enterobacter cloacae and the same (12.5 mg/mL) for Proteus vulgaris, Klebsiella oxytoca, Klebsiella aerogenes and Proteus mirabilis. Based on the above mentioned figures, it appears that strains of pathogenic fungi tested are generally much more sensitive to crude extracts than strains of bacteria. In fact, antimicrobial activities of the 3 crude extracts tested are stronger on human pathogenic fungi than bacteria. These results are evidence that carpophores of the 3 mushrooms species could be a source of new molecules potentially more effective than synthetic products against some human pathogenic fungi and bacteria.
Suggested Citation
Handle:
RePEc:epw:ejbio0:v:1:y:2020:i:5:id:17097
DOI: 10.24018/ejbio.2020.1.5.97
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejbio0:v:1:y:2020:i:5:id:17097. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejbio .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.